Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Resverlogix Corp T.RVX

Alternate Symbol(s):  RVXCF

Resverlogix Corp. is a Canada-based late-stage biotechnology company. The Company is engaged in epigenetics, with a focus on developing therapies for the benefit of patients with chronic diseases. Its epigenetic therapies are designed to regulate the expression of disease-causing genes. The Company's clinical program is focused on evaluating its lead candidate apabetalone (RVX-208) for the treatment of cardiovascular disease and associated comorbidities, and post-COVID-19 conditions. RVX-208 is a small molecule that is a selective bromodomain and extra-terminal (BET) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. RVX-208 is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. It partners with EVERSANA, to support the commercialization of RVX-208 for cardiovascular disease, post-COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States.


TSX:RVX - Post by User

Bullboard Posts
Post by toinv261on Jun 03, 2014 1:08pm
210 Views
Post# 22625356

Time

TimeI guess the one good thing about hearing nothing as we move toward the one year anniversary is that with each day the probability of hearing an announcement increases because at some point something has got to be announced.

I'm betting that what we're going to hear will be very positive, IMO.
  1. We don't know if BP is involved or not but there is a good chance given the need for most of these companies to dial up their chances for new compounds for their pipelines.
  2. The areas of health focus are huge, protected by patents and highly profitable for years - cardiovascular disease, diabetes, cancer, etc.
  3. Eastern was in at $1.18 for 14,819,476 shares on Nov 29, 2011.
  4. Eastern came in again at $.90 for $1,765,307 shares on Aug 14, 2014 (after the trial results and pre post hoc results). This is a very strong endorsement.
  5. Eastern may have a had partners scooping up shares when they were down in the $.15 to $.30 range in late June and early July, 2013. This, of course is pure speculation.
  6. Eastern & NGN both came in through Zenith with $8,000,000 this winter. This is clearly a very strong endorsement of the RVX scientific capability, and this is absolutely critical.

With KD/Eastern being worth billions they have lot's of room at the top of their investment pyramid (high risk investments) to play. They could easily walk away from RVX but they haven't. This suggests to me that they have gained enough confidence in the RVX and Zenith science to continue support. There is a tremendous level of institutional scientific knowledge at RVX, Zenith and NGN.

I would guess a CVR with a very high initial payout and then high long term royalties could be very appealing to Eastern. What we know at this stage is that Eastern and NGN are still in for the party and that makes me feel reassured.

On a separate issue, does anyone know anything about the diabetes trial?
  1. Where is it being conducted?
  2. Who is the trial agency?
  3. Size of sample and sample structure?
  4. Is it still in field of at the analytical stage?
  5. Time of results?

Perhaps the silence is because they are deep into negotiations.

GLTA. IMO. DYODD.
Cheers
Toinv




Bullboard Posts